UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 13, 2018
AEGLEA BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-37722 |
|
46-4312787 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin, TX |
78746 |
|
(Address of principal executive offices) |
(Zip Code) |
(512) 942-2935
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 13, 2018, the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) appointed Bryan Lawlis as a Class III director.
Dr. Lawlis will receive an annual cash retainer of $37,500 per year in accordance with the Company’s existing compensation policy for non-employee directors. In addition, the Board granted to Dr. Lawlis, effective July 13, 2018, a stock option to purchase 36,800 shares of common stock at an exercise price of $8.78 per share, which will vest monthly over three years, subject to Dr. Lawlis’s continued service to the Company.
The Company has entered into its standard form of indemnification agreement with Dr. Lawlis. A form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 14, 2015.
There is no arrangement or understanding with any person pursuant to which Dr. Lawlis was appointed as a member of the Board, and Dr. Lawlis does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
AEGLEA BIOTHERAPEUTICS, INC. |
||
|
|
|
|
|
|
|
|
|
Date: July 16, 2018 |
|
|
|
By: |
|
/s/ Charles N. York II |
|
|
|
|
|
|
|
Charles N. York II |
|
|
|
|
|
|
|
Chief Financial Officer |
3